EPISODE · May 13, 2026 · 2 MIN
COMPASS Pathways' COMP360: A Game-Changer for Treatment-Resistant Depression
from The Daily News Now! Business
COMPASS Pathways has reported positive phase three trial results for their psychedelic therapy COMP360, treating treatment-resistant depression. Theyre submitting a new drug application to the FDA, aiming for approval by year-end. With a Commissioners National Priority Voucher and potential DEA rescheduling, COMP360 could become a blockbuster drug, reducing healthcare costs for the four million affected individuals. Theyre also advancing PTSD trials and have a strong cash runway. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/c0382854958e1592
NOW PLAYING
COMPASS Pathways' COMP360: A Game-Changer for Treatment-Resistant Depression
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m